Evidence-Based Medical News

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine OB/GYN & Women's Health Orthopedics & Sports Medicine Genetics & Precision Medicine Radiology & Imaging Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Hematology Dermatology Urology Emergency Medicine Ophthalmology Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

valsartan

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of valsartan

38 trials tracked of valsartan: 30 in phase 3 or 4 and 10 with published results. The most-cited published study has 175 citations.

38Trials tracked

30Phase 3 & 4

0Recruiting

10With published results

Phase distribution

Phase 4 12 Phase 3 18 Phase 2 8

Phase 4 EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study) Completed · 175 cited
Phase 3 A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients Completed · 157 cited
Phase 3 Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction Completed · 88 cited
Phase 3 The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI Completed · 61 cited
Phase 3 Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF) Completed · 25 cited
Phase 3 A Study to Evaluate the Long-term Use of Valsartan in Children 6 Months to 5 Years Old With Hypertension Completed · 22 cited

Show 32 more trials

Phase 3 Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI Completed · 16 cited
Phase 3 24 Hour Ambulatory Cardiac Oxygen Consumption Completed · 16 cited
Phase 3 Cardioprotective Benefits of Carvedilol-CR or Valsartan Added to Lisinopril Completed · 10 cited
Phase 3 Azilsartan Medoxomil (TAK-491) Compared to Valsartan in Chinese Participants With Hypertension Completed · 8 cited
Phase 4 The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients Completed
Phase 4 Valsartan Intensified Primary Care Reduction of Blood Pressure Study Completed
Phase 4 8 Weeks Study to Evaluate the Efficacy and Safety of Valsartan in Combination With Aliskiren Compared to Valsartan Alone in Patients With Stage 2 Hypertension Completed
Phase 4 Black Education and Treatment of Hypertension (BEAT HTN) Completed
Phase 4 The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction Completed
Phase 4 Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study) Completed
Phase 4 To Demonstrate Non-inferiority of Combination of 5 mg Amlodipine/ 80 mg Valsartan to 160 mg Valsartan Alone Completed
Phase 4 Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Compared to Valsartan Monotherapy or Hydrochlorothiazide Monotherapy in Elderly (>70) With Mild-moderate Hypertension. Completed
Phase 4 Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus Completed
Phase 4 Efficacy of a Combination of Amlodipine/Valsartan on 24H Blood Pressure Control With One Nocturnal or Diurnal Intake a Day Completed
Phase 4 Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone Completed
Phase 3 Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age Completed
Phase 3 Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction Completed
Phase 3 Efficacy and Safety of Valsartan in Combination With Amlodipine Compared to Losartan Plus Hydrochlorothiazide in Patients With Hypertension and Left Ventricular Hypertrophy Completed
Phase 3 Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension Completed
Phase 3 Effect of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children With High Blood Pressure Completed
Phase 3 Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension Completed
Phase 3 An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension. Completed
Phase 3 A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide. Completed
Phase 3 Safety and Efficacy of Valsartan vs Atenolol and Hydrochlorothiazide Combination on Blood Flow in Hypertensive Patients Completed
Phase 2 Efficacy and Safety of Aliskiren in Patients With Mild to Moderate Hypertension During Exercise Completed
Phase 2 Efficacy and Safety of LCZ696A in Patients With Essential Hypertension Completed
Phase 2 Study of Inflammation and Oxidative Stress in Persons Undergoing Dialysis Completed
Phase 2 Effect of Valsartan on Carotid Artery Disease Completed
Phase 2 LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction Completed
Phase 2 Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension Completed
Phase 2 Sodium Excretion of LCZ696 in Patients With Hypertension; Heart Failure and Healthy Volunteers Completed
Phase 2 An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension Completed

Showing the 38 most-cited and recently-updated of 38 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.